 DARTMOUTH, Nova Scotia--BUSINESS WIRE--- IMV BreastCancer--IMV Inc. Nasdaq: IMV; TSX: IMV IMV or the Company, a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies, today announced that its lead compound, maveropepimut-S DPX-Survivac will be investigated in patients with hormone receptor positiveHER2-negative HRHER2- breast cancer. HRHER2- tumors represent an unmet clinical need with relatively poor responses to neoadjuvant endocrine treatment1. This inves 